Perspective Therapeutics, Inc. cash flow statement

In fiscal 2023, Perspective Therapeutics, Inc.'s operations generated −$36.9m of cash; it spent $1.1m on capital projects, leaving free cash flow of −$38.0m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Perspective Therapeutics, Inc.: cash flow statement, annual
Fiscal year	2011Jun 2011	2012Jun 2012	2013Jun 2013	2014Jun 2014	2015Jun 2015	2016Jun 2016	2017Jun 2017	2018Jun 2018	2019Jun 2019	2020Jun 2020	2021Jun 2021	2022Dec 2022	2023Dec 2023
Cash from operations	−2	−2	−3	−3	−4	−4	−6	−6	−5	−4	−3	—	−37
Depreciation and amortisation	1	1	1	1	1	0	0	0	0	0	0	—	1
Stock-based pay	0	0	0	0	0	0	0	0	0	0	0	—	4
Capital spending	0	0	0	0	0	0	1	0	0	0	0	0	1
Free cash flow	−3	−3	−3	−3	−4	−4	−6	−6	−5	−4	−3	—	−38
Free cash flow after stock pay	−3	−3	−3	−3	−4	−5	−7	−6	−6	−4	−4	—	−42
Shares issued	0	2	3	14	0	0	—	0	—	—	—	—	0

US$ millions unless shown otherwise. Fiscal quarters.

Perspective Therapeutics, Inc.: cash flow statement, quarterly
Quarter	2022 Q1Mar 2022	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022	2023 Q1Mar 2023	2023 Q2Jun 2023	2023 Q3Sept 2023	2023 Q4Dec 2023
Cash from operations	−1	−3	−2	−4	−10	−8	−10	−9
Depreciation and amortisation	0	0	0	0	0	0	0	0
Stock-based pay	0	0	0	0	1	1	0	1
Capital spending	0	0	0	0	0	1	0	0
Free cash flow	−1	−3	−2	−4	−10	−9	−10	−9
Free cash flow after stock pay	−2	−3	−2	−5	−11	−10	−11	−10
Shares issued	0	0	—	—	—	—	—	—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Perspective Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Perspective Therapeutics, Inc.